10 Best Performing Penny Stocks So Far in 2025

6. Compass Therapeutics, Inc. (NASDAQ:CMPX)

Year-to-Date Performance: 137.86%

Share Price: $3.33

Number of Hedge Fund Holders: 14

Compass Therapeutics, Inc. (NASDAQ:CMPX) is one of the best-performing penny stocks so far in 2025. On July 14, Stifel reiterated its “Buy” rating for Compass Therapeutics, Inc. (NASDAQ:CMPX) with a price target of $11. This decision came after investor meetings with the company’s management.

According to the research firm, the extended timeline for overall survival event accrual in the Phase 2/3 COMPANION-002 trial is a good thing. The trial is testing paclitaxel with or without tovecimig in patients with second-line biliary tract cancer.

Compass Therapeutics, Inc. (NASDAQ:CMPX) now expects to share the topline data in the fourth quarter of 2025. This means patients will be followed up for more than 19 months on average. Stifel noted that this is important because in this disease, the overall survival of the control arm rarely goes beyond 6 months.

Besides the COMPANION-002 trial, Stiefl analysts believe upcoming data disclosures for two other compounds in the second half of 2025 could potentially prove to be important catalysts for Compass Therapeutics, Inc. (NASDAQ:CMPX). These include Phase 1 dose-escalation data for CTX-8371, a PD-1xPD-L1 bispecific antibody, and preclinical data for CTX-10726, a PD-1xVEGF-A bispecific antibody.

Compass Therapeutics, Inc. (NASDAQ:CMPX) is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics. The company focuses on the relationship between angiogenesis, the immune system, and tumor growth.